Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo.

Blood
Eunice S WangMalcolm A S Moore

Abstract

The role of angiogenesis in lymphoproliferative diseases is not well established. We demonstrate here that human lymphoma cells secrete vascular endothelial growth factor (VEGF) and express VEGF receptor 1 (VEGFR-1) and VEGFR-2. Proliferation of non-Hodgkin lymphoma (NHL) cells under serum-free conditions was enhanced by the addition of VEGF and was blocked by VEGFR-1- and VEGFR-2-specific antibodies. To differentiate between VEGF-mediated autocrine and paracrine effects on lymphoma growth, NOD/SCID mice engrafted with human diffuse large B-cell lymphoma (DLBCL) were treated with species-specific antibodies against human VEGFR-1 (6.12), human VEGFR-2 (IMC-1C11), murine VEGFR-1 (MF-1), or murine VEGFR-2 (DC101). Treatment with 6.12 or DC101 (targeting tumor VEGFR-1 and host VEGFR-2) reduced established DLBCL xenograft growth, whereas treatment with IMC-1C11 or MF-1 (targeting tumor VEGFR-1 and host VEGFR-1) had no effect. Decreased tumor volumes after 6.12 and DC101 treatment correlated with increased tumor apoptosis and reduced vascularization, respectively, supporting the presence of autocrine VEGFR-1- and paracrine VEGFR-2-mediated pathways in lymphomagenesis. Inhibition of paracrine VEGF interactions (DC101) in these models ...Continue Reading

References

Jan 1, 1979·Rheumatology and Rehabilitation·D Jentsch
Jan 1, 1974·Journal of the National Cancer Institute·P ArnsteinE H Lennette
Feb 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·R MasoodP S Gill
Aug 25, 1999·British Journal of Haematology·F BertoliniG Martinelli
Aug 23, 2000·The Journal of Clinical Investigation·S DiasS Rafii
Mar 20, 2001·Current Oncology Reports·D E Weng, N Usman
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·S DiasS Rafii
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Aug 6, 2002·Journal of Neuro-oncology·James RubensteinMarc Shuman
Sep 5, 2002·The Journal of Pathology·Ipatia A Doussis-AnagnostopoulouKevin C Gatter
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frank A Scappaticci
Oct 3, 2002·Nature Reviews. Cancer·Robert Kerbel, Judah Folkman
Dec 4, 2002·The Journal of Experimental Medicine·Janice A NagyHarold F Dvorak
Apr 25, 2003·International Journal of Cancer. Journal International Du Cancer·William LeendersRobert M W de Waal
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar

❮ Previous
Next ❯

Citations

Aug 19, 2007·Journal of Cancer Research and Clinical Oncology·Kristen N GanjooCaroline S An
Aug 23, 2006·Journal of Mammary Gland Biology and Neoplasia·Arthur M MercurioRobin E Bachelder
Dec 18, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J RuanJ P Leonard
Oct 15, 2005·Current Opinion in Oncology·Ad Koster, John M M Raemaekers
Jun 2, 2005·Current Opinion in Hematology·Samer Aboudola, Ameet R Kini
Jun 23, 2006·Journal of Clinical Pathology·Alexandar TzankovStephan Dirnhofer
Dec 6, 2006·Cancer Research·Rosandra N KaplanDavid Lyden
Oct 28, 2010·The Journal of Clinical Investigation·Dhanalakshmi ChinnasamySteven A Rosenberg
Sep 26, 2013·Cancer Cell International·Melanie Hein, Shannon Graver
Jan 13, 2011·Cellular & Molecular Biology Letters·Keiko DoiSenji Shirasawa
Mar 8, 2011·Cancer Chemotherapy and Pharmacology·Martha RomeroAnne Janin
Nov 23, 2005·Expert Opinion on Therapeutic Targets·Laura Sanz, Luis Alvarez-Vallina
May 6, 2015·Cancers·Ranjan UpadhyayJoshua D Brody
Apr 22, 2015·International Journal of Molecular Sciences·Maria Christina TsourlakisStefan Steurer
Aug 13, 2008·Expert Opinion on Investigational Drugs·M SlevinJ Krupinski
Jun 10, 2008·Expert Opinion on Emerging Drugs·Shireen Kassam, Silvia Montoto
Jun 7, 2005·Expert Opinion on Emerging Drugs·Henk M W Verheul, Herbert M Pinedo
Jan 13, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Berber D RoordaEveline S J M de Bont
Nov 2, 2007·Journal of the American Academy of Dermatology·Kiyoshi MoriharaSaburo Kishimoto
Dec 26, 2006·Critical Reviews in Oncology/hematology·Xunwei DongRenchi Yang
Jun 11, 2005·European Journal of Haematology·Fanny ReichertZina Ben-Ishay
Apr 25, 2008·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Kimberly A JacobsenLouis C Gerstenfeld
Dec 6, 2008·International Journal of Cancer. Journal International Du Cancer·Whitney A SpannuthAnil K Sood
May 4, 2006·International Journal of Cancer. Journal International Du Cancer·Yan WuDaniel J Hicklin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis